Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antineoplastons in Neurofibroma and Schwannoma
NCT02988726Phase 2Terminated
- Sponsor
- Burzynski Research Institute
- Start
- Mar 1999
- Primary completion
- Aug 2001
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of antineoplaston A10 and antineoplaston AS2-1 in neurofibroma and schwannoma, sponsored by Burzynski Research Institute. Primary endpoint: Number of Participants with Objective Response at 12 months. Started Mar 1999; status: terminated.
02
Drugs
antineoplaston A10antineoplaston AS2-1
03
Conditions
neurofibromaschwannoma
Beyond the preview
Go deeper on NCT02988726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02988726.